ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Abstract titles reveal some of ASCO’s key datasets.
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.
One of the first human datasets concerning an ATM inhibitor shows glioblastoma’s intractability.
Selectively hitting PARP1 is meant to reduce toxicity, and arguably the Petra trial shows this.
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
A roundup of the first quarter's key oncology drug approvals and rejections.